Leptomeningeal Metastases in HER2+ Breast Cancer
A neuro-oncologist explains the prevalence of leptomeningeal metastases in HER2+ breast cancer and her preferred method of treatment.
Neratinib for Metastatic HER2+ Breast Cancer and Brain Metastases
Oncologists debate the use of neratinib for metastatic HER2+ breast cancer treatment in the context of the HER2CLIMB clinical trial data on tucatinib.
Maintenance Therapy Duration and Considerations for Treatment Interruption
Experts comment on the typical urothelial cancer maintenance therapy duration in their practice, and situations in which they might consider interrupting treatment while maintaining patient response.
Treatment for Cisplatin-Ineligible Patients with High PD-L1 Expression
Petros Grivas, MD, PhD, shares a clinical scenario of a cisplatin-ineligible patient with high PD-L1 expression and lymph node metastases, and experts weigh in on recommended treatment options.
Maintenance Therapy Strategies for Transplant Eligible Multiple Myeloma
Drs Ajay Nooka and Jonathan Kaufman discuss maintenance and consolidation treatment strategies for transplant eligible multiple myeloma.
Matthew Krebs, MB, PhD, Reviews the Next Steps for Subcutaneous Amivantamab in Solid Tumors
Matthew Krebs, MB, PhD, spoke about how subcutaneous amivantamab can best be utilized in future clinical trials.
Treatment Approaches for Patients with Newly Diagnosed Multiple Myeloma
Experts discuss how they select a treatment regimen for a newly diagnosed multiple myeloma patient, and how they measure a successful treatment response.
Advice for Community Oncologists Treating Renal Cell Carcinoma
Dr Scott Tykodi provides advice for community oncologists managing patients with renal cell carcinoma.
Peter Humphrey, MD, PhD, Discusses Current Role of Pathology in RCC
At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about the role of pathology in renal cell carcinoma.
Nicolas Girard, MD, on the Safety Profile of Nivolumab Plus Chemotherapy in Resectable NSCLC
Nicolas Girard, MD, speaks with CancerNetwork® about the updated safety findings of nivolumab and chemotherapy in resectable non–small cell lung cancer.
David M. O’Malley, MD, Reviews the Benefit of Pembrolizumab for Endometrial Cancer
David M. O’Malley, MD, spoke about unmet needs of patients with advanced microsatellite instability–¬high or mismatch repair deficient endometrial carcinoma and the clinical benefit pembrolizumab provides.
Frontline Treatment Options for Early-Stage HER2+ Breast Cancer
Sarah M. Tolaney, MD, MPH, reviews the treatment options for patients with early-stage HER2+ breast cancer in the frontline setting.
Goals of Care for Patients with Early-Stage versus Advanced or Metastatic HER2+ Breast Cancer
Sarah M. Tolaney, MD, MPH, provides an overview of how goals of care and prognosis differ between patients with early-stage HER2+ breast cancer and advanced or metastatic HER2+ breast cancer.
Use of Inotuzumab for ALL in the Frontline Setting
Nikesh Shah, MD, presents a trial published in Lancet Oncology in 2018 on the use of inotuzumab plus mini-CVD in the frontline setting for older patients with ALL.
Team Introductions: The Moffitt Marrowvingians vs The Memorial Sloan-Kettering Mavericks
Steven Frommeyer kicks off a new and exciting competitive series from CancerNetwork® and introduces the first 2 teams.
Role of Immunotherapy in Newly Diagnosed NSCLC
A broad discussion on the role of immunotherapy in newly diagnosed NSCLC in both the neoadjuvant and adjuvant settings.
Patient Profile 1: Stage IIB NSCLC With High PD-L1 Expression
Shared insight on a patient profile of newly diagnosed non–small cell lung cancer with high PD-L1 expression and no driver mutation.
Nina Shah, MD, Shares Key Takeaways From Phase 2 KarMMa Trial Sub-Analysis of Ide-Cel in R/R Multiple Myeloma
Nina Shah, MD, spoke about her key takeaways from a sub-analysis of the phase 2 KarMMa trial assessing correlates of complete response among those treated with idecabtagene vicleucel in relapsed/refractory multiple myeloma.
Catherin Watson, MD, Assesses the Future of Genetic Testing in Ovarian Cancer
At SGO 2022, Catherine Watson, MD, spoke about how to encourage patients with ovarian cancer to seek genetic testing.
Common Adverse Events with Single-Agent or Combination Therapy
Mehmet Asim Bilen, MD, provides an overview of commonly observed adverse events in patients with metastatic RCC receiving single-agent or combination therapy.
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Maintenance Therapy Duration and Considerations for Treatment Interruption")
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Nicolas Girard, MD, speaks with CancerNetwork® about the updated safety findings of nivolumab and chemotherapy in resectable non–small cell lung cancer.")
